Clinical Trial

Phase II Study of QL1706 Combined With Paclitaxel and Bevacizumab for Second-Line Immune Rechallenge in Gastric Cancer

Name: Phase II Study of QL1706 Combined With Paclitaxel and Bevacizumab for Second-Line Immune Rechallenge in Gastric Cancer — clinical trial record (NCT07045805)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

The study aims to evaluate the efficacy and safety of the QL1706 combination with paclitaxel and bevacizumab in patients with gastric adenocarcinoma and gastroesophageal junction adenocarcinoma who have failed first-line standard therapy.

Trial Details

NCT Number	NCT07045805
Lead Sponsor	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Conditions	Gastric Cancer (GC)
Enrollment	66 participants
Start Date	2025-07-25
Primary Completion	2027-07-31 (estimated)
Study Completion	2028-03-31 (estimated)
Updated on ClinicalTrials.gov	2025-07-01